A sol-gel-based reverse-phase microarray was developed with improved sensitivity for prostatespecific antigen (PSA) from serum. The pore-sizecontrolled 3D sol-gel matrix was created with a large surface area to capture target molecules densely. Using the optically active sol-gel nanocomposites, human female serum was spiked with PSA and assessed using the reverse-phase protein microarray. The reverse-phase assay exhibited a limit of detection of 1 pg/mL for PSA and a dynamic range of 103 orders of magnitude. Notably, the platform matched the demand of the immunoassay in a simple and feasible manner. Moreover, the platform shortened the total assay time with an increased accuracy of diagnosis.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
MacBeath, G. & Schreiber, S.L. Printing proteins as microarrays for high-throughput function determination. Science 289, 1760–1763 (2000).
Hall, D.A., Ptacek, J. & Snyder, M. Protein microarray technology. Mech. Ageing Dev. 128, 161–167 (2007).
Sreekumar, A. et al. Profiling of cancer cells using protein microarrays: discovery of novel radiation-regulated proteins. Cancer Res. 61, 7585–7593 (2001).
Järås, K. et al. Reverse-phase versus sandwich antibody microarray, technical comparison from a clinical perspective. Anal. Chem. 79, 5817–5825 (2007).
Spurrier, B., Ramalingam, S. & Nishizuka, S. Reversephase protein lysate microarrays for cell signaling analysis. Nat. Protoc. 3, 1796–1808 (2008).
LaBaer, J. & Ramachandran, N. Protein microarrays as tools for functional proteomics. Curr. Opin. Chem. Biol. 9, 14–19 (2005).
Paweletz, C.P. et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncology 20, 1981–1989 (2001).
Sheehan, K.M. et al. Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol. Cell. Proteomics 4, 345–355 (2005).
Rupcich, N., Goldstein, A. & Brennan, J.D. Optimization of sol-gel formulations and surface treatments for the development of pin-printed protein microarrays. Chem. Mat. 15, 1803–1811 (2003).
Lee, M.Y., Dordick, J.S. & Clark, D.S. Metabolizing enzyme toxicology assay chip (MetaChip) for highthroughput microscale toxicity analyses. Proc. Natl. Acad. Sci. U. S. A. 102, 983–987 (2005).
Lee, S. et al. Chip-based detection of hepatitis C virus using RNA aptamers that specifically bind to HCV core antigen. Biochem. Biophys. Res. Commun. 358, 47–52 (2007).
Gill, I. Bio-doped nanocomposite polymers Sol-gel bio-encapsulates. Chem. Mat. 13, 3404–3421 (2001).
Kim, S. et al. Improved sensitivity and physical properties of sol-gel protein chips using large-scale material screening and selection. Anal. Chem. 78, 7392–7396 (2006).
Ressine, A. et al. Macro/nano-structured silicon as solid support for antibody arrays. Anal. Chem. 75, 6968–6974 (2003).
Bensalah, K., Lotan, Y., Karam, J.A. & Shariat, S.F. New circulating biomarkers for prostate cancer. Prostate Cancer Prostatic Dis. 11, 112–120 (2008).
Smith, D.S., Humphrey, P.A. & Catalona, W.J. The early detection of prostate carcinoma with prostate specific antigen. Cancer 80, 1852–1856 (1997).
Healy, D.A. et al. Biosensor developments: application to prostate-specific antigen detection. Trends Biotechnol. 25, 125–131 (2007).
Ahyai, S.A. et al. Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostatespecific antigen level < or=4.0 ng per milliliter. Eur. Urol. 53, 750–757 (2008).
Morgentaler, A. & Rhoden, E.L. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less. Urology 68, 1263–1267 (2006).
Thompson, I.M. et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N. Engl. J. Med. 350, 2239–2246 (2004).
Carter, H.B. et al. Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. Urology 49, 379–384 (1997).
Shchipunov, Y.A. Sol-gel-derived biomaterials of silica and carrageenans. J. Colloid Interface Sci. 268, 68–76 (2003).
Henry, N., Parce, J.W. & McConnell, H.M. Visualization of specific antibody and C1q binding to haptensensitized lipid vesicles. Proc. Natl. Acad. Sci. U. S. A. 75, 3933–3937 (1978).
Lilja, H. et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin. Chem. 37, 1618–1625 (1991).
Laurell, T., Wallman, L. & Nilsson, J. Design and development of a silicon micro-fabricated flow-through cell for on-line picolitre sample handling. J. Micromech. Microeng. 9, 369–376 (1999).
Pawlak, M. et al. Zeptosens’ protein microarrays: A novel high performance microarray platform for low abundance protein analysis with robust and simplicity. Proteomics 2, 283–393 (2002).
Wulfkuhle, J.D. et al. Signal pathway profiling of ovarian cancer from human tissue specimens using reversephase protein microarrays. Proteomics 3, 2085–2090 (2003).
Nishizuka, S. et al. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc. Natl. Acad. Sci. U. S. A. 100, 14229–14234 (2003).
Finnskog, D.K. et al. High-speed biomarker identification utilizing porous silicon nanovial arrays and MALDI-TOF mass spectrometry. Electrophoresis 27, 1093–1103 (2006).
Järås, K. et al. ENSM: Europium nanoparticles for signal enhancement of antibody microarrays on nanoporous silicon. J. Proteome Res. 7, 1308–1314 (2008).
About this article
Cite this article
Lee, S., Laurell, T., Jeong, O.C. et al. Development of a Sol-gel-assisted Reverse-phase Microarray Platform for Simple and Rapid Detection of Prostate-specific Antigen from Serum. BioChip J 12, 69–74 (2018). https://doi.org/10.1007/s13206-017-2109-8
- Sol-gel microarray
- Macro/nano-structure silicon
- Reverse-phase assay
- Prostate-specific antigen
- Prostate cancer